Since 1993, GoeGoe Honglin Pharm. has entered the Chinese market. Today, GoeGoe Honglin Pharm. has established modern R&D centers and production bases compliant with GMP standards in Beijing and Zhenjiang, Jiangsu.

As important manufacturing platforms for GoeGoe Honglin Pharm. in China, the Beijing and Zhenjiang facilities are equipped with critical machinery imported from the United States, Germany, and Japan, ensuring that both equipment performance and pharmaceutical manufacturing processes meet internationally leading standards.

⭐Beijing Honglin Pharmaceutical Co., Ltd.

Located in Yanqi Industrial Development Zone, Huairou District, Beijing, the company is the first localized R&D and manufacturing base established by GoeGoe Honglin Pharmaceutical Co. in China. With a registered capital of USD 15.8 million, it is a wholly U.S.-owned, certified National High-Tech Enterprise. The company is equipped with internationally advanced pharmaceutical manufacturing equipment and intelligent quality control systems, and receives technical support from a U.S.-based expert management team.

⭐GoeGoe Honglin Biopharmaceutical (Jiangsu) Co., Ltd

Located in Zhenjiang Economic and Technological Development Zone, Jiangsu Province, the company serves as another strategic expansion by GoeGoe Honglin Pharmaceutical Co. following Beijing Honglin Pharmaceutical Co., Ltd. With a registered capital of USD 30 million and a site covering approximately 80,000 square meters, the facility is equipped with multiple automated production lines and imported core process equipment, integrated with advanced information systems and environmental control systems, thereby comprehensively ensuring both product quality and production efficiency. The first phase of the Jiangsu base has been successfully completed and is now operational. It has an annual production capacity of 2.4 billion tablets and 600 million capsules, which demonstrates highly efficient and stable commercial manufacturing capabilities.